Biotricity(BTCY.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Biotricity
BTCY.US
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a Holter and Extended Holter monitors for cardiac diagnostics; Biocare which support medical practitioners to gather data, and regularly monitor and treat patients with two or more chronic care conditions; Bioheart that offers preventative care and disease management solutions; and Biokit, a remote patient monitoring kit for cardiac patients that had other chronic conditions such as hypertension or COPD. Biotricity, Inc.
63.95 B
BTCY.USMarket value -Rank by Market Cap -/-

Financial Score

19/01/2026 Update
C
Health Care TechnologyIndustry
Industry Ranking28/47
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE15.07%A
    • Profit Margin-30.02%E
    • Gross Margin81.88%A
  • Growth ScoreB
    • Revenue YoY19.51%B
    • Net Profit YoY69.67%A
    • Total Assets YoY19.48%A
    • Net Assets YoY-11.19%D
  • Cash ScoreC
    • Cash Flow Margin-309.85%D
    • OCF YoY19.51%B
  • Operating ScoreA
    • Turnover2.6A
  • Debt ScoreE
    • Gearing Ratio578.90%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Biotricity | 8-K: FY2026 Q2 Revenue: USD 3.9 M

    LB filings·
    US
    BTCY
    -1.17%
    LB filings·
    US
    BTCY
    -1.17%

    Biotricity’s Earnings Call: Growth and Positive Outlook

    Biotricity's Q2 earnings call highlights significant revenue growth of 19% to $3.9 million, improved gross profit by 29.4% to $3.2 million, and positive EBITDA of $373,000. Despite a net loss of $772,000 and increased operating expenses, strategic advancements in cardiac monitoring technology and market expansion suggest a promising outlook. The company aims for continued growth and profitability through innovation and strategic partnerships.

    Tip Ranks·
    US
    BTCY
    -1.17%
    Tip Ranks·
    US
    BTCY
    -1.17%

    Biotricity Inc. Reports Revenue Growth Amid Financial Challenges

    Biotricity Inc. reported Q2 earnings with revenue growth to $7.76 million, up from $6.47 million in 2024, driven by technology fees and device sales. Despite a net loss of $1.36 million, improved from $5.26 million last year, the company achieved a positive operating profit of $555,764. Management remains optimistic, focusing on revenue growth, liquidity improvements, and strategic initiatives to address financial challenges.

    Tip Ranks·
    US
    BTCY
    -1.17%
    Tip Ranks·
    US
    BTCY
    -1.17%

    Biotricity Inc. ( BTCY ) Reports Q2 Loss, Lags Revenue Estimates

    Biotricity (BTCY) delivered earnings and revenue surprises of +62.50% and -0.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Commentary·
    US
    BTCY
    -1.17%
    Zacks Commentary·
    US
    BTCY
    -1.17%

    Biotricity | 10-Q: FY2026 Q2 Revenue: USD 3.886 M

    LB filings·
    US
    BTCY
    -1.17%
    LB filings·
    US
    BTCY
    -1.17%
    © 2026 Longbridge｜Disclaimer